NASDAQ:ITUS ITUS (ITUS) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free ITUS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.61▼$4.7650-Day Range N/A52-Week Range$1.83▼$6.43Volume69,859 shsAverage Volume134,373 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ITUS alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About ITUS Stock (NASDAQ:ITUS)Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.Read More Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. ITUS Stock News HeadlinesApril 30, 2024 | msn.comHow has California's new fast food minimum wage affected menu prices?April 27, 2024 | msn.comStrong winds topple large East Texas trees in overnight stormsApril 26, 2024 | msn.comHexagon AB Non-GAAP EPS of €0.08, revenue of €1.3BApril 26, 2024 | msn.com22 year-old Titus County fugitive apprehended in MissouriApril 25, 2024 | msn.comAbout U.S.$ 3 Million Made From Planks Unaccounted for At FDAApril 25, 2024 | msn.comUS Senate passes TikTok divestment-or-ban bill; ByteDance faces a tough choice, set to challenge itApril 22, 2024 | msn.comBuilt by 'Bama: Nick and Terry Saban help build 21st Habitat houseApril 7, 2024 | msn.comClear skies for your SundayApril 6, 2024 | msn.comCool temperatures expected for your SaturdayApril 5, 2024 | msn.comHexagon acquires Virginia-based Itus DigitalApril 4, 2024 | finanznachrichten.deHexagon rebrands Qognify, reaffirming commitment to physical securityApril 4, 2024 | finance.yahoo.comHexagon acquires Itus Digital to expand Asset Performance Management capabilitiesApril 2, 2024 | msn.comStellenbosch cement second spot with victory over Kaizer ChiefsMarch 27, 2024 | msn.comMan arrested in Titus County sex sting operationMarch 23, 2024 | nasdaq.comMay 3rd Options Now Available For Eli Lilly (LLY)March 18, 2024 | msn.comSome bay clouds Monday with sunny and warm afternoonMarch 17, 2024 | msn.comSunny skies for your SundayMarch 11, 2024 | msn.com"A kit with some surprising tricks up its sleeve": Donner Backbeat reviewMarch 9, 2024 | msn.comFactChecking Biden’s State of the UnionMarch 7, 2024 | msn.comSeven candidates for three seats on 5th District Court of Appeals, in all-GOP affairFebruary 21, 2024 | msn.comITU's AI for Good Global Summit 2024 puts tech to the test for people and planetFebruary 19, 2024 | msn.comChapel Hill ISD announces $9.3 million bond election for MayFebruary 13, 2024 | msn.comUS Senate Passes Ukraine Aid Bill, House Likely To Reject ItFebruary 6, 2024 | ft.comLetter: One way to raise quality of classroom discussionsJanuary 26, 2024 | msn.comSeasonably cool Thursday with sunshineSee More Headlines Receive ITUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ITUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/09/2018Today5/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Patent Owners & Lessors Sub-IndustryN/A Current SymbolNASDAQ:ITUS CUSIPN/A CIK715446 Webwww.ituscorp.com Phone(408) 708-9808FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesAmit D. KumarExecutive Chairman, President & CEOMichael J. CatelaniSecretary, Chief Operating & Financial OfficerThomas SchlumpbergerExecutive Vice President-DiagnosticsKey CompetitorsEqonexNASDAQ:EQOSFull Truck AllianceNYSE:YMMIntegrated Media TechnologyNASDAQ:IMTEOnion GlobalNYSE:OGBLYRenovare EnvironmentalNASDAQ:RENOView All Competitors ITUS Stock Analysis - Frequently Asked Questions How were ITUS's earnings last quarter? ITUS Co. (NASDAQ:ITUS) released its quarterly earnings data on Friday, March, 9th. The business services provider reported ($0.11) EPS for the quarter. What other stocks do shareholders of ITUS own? Based on aggregate information from My MarketBeat watchlists, some companies that other ITUS investors own include Synergy Pharmaceuticals (SGYP), Galectin Therapeutics (GALT), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Halozyme Therapeutics (HALO), Palatin Technologies (PTN), Advanced Micro Devices (AMD), Coherus BioSciences (CHRS) and CME Group (CME). This page (NASDAQ:ITUS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ITUS Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.